A newly identified COVID-19 subvariant, NB.1.8.1, is rapidly spreading across multiple countries, including Australia, the United States, and regions in Asia. This subvariant, a descendant of the Omicron lineage, has been designated a “variant under monitoring” by the World Health Organization due to its increased transmissibility and potential to partially evade immunity from prior infections or vaccinations.

Characteristics and Spread

NB.1.8.1 carries several mutations in the spike protein, notably T22N, F59S, G184S, A435S, V445H, and T478I. These mutations may enhance the virus’s ability to bind to human cells, potentially increasing its transmissibility. Laboratory studies suggest that NB.1.8.1 has a stronger binding affinity to the human ACE2 receptor compared to earlier strains, which could facilitate more efficient cell infection.

In Australia, NB.1.8.1 has become the dominant variant in several states. For instance, it accounts for over 40% of sequenced cases in Victoria and is prevalent in Western Australia. Wastewater surveillance has confirmed its widespread presence, indicating community transmission.

Symptoms and Severity

The symptoms associated with NB.1.8.1 are similar to those of previous Omicron subvariants. Common symptoms include sore throat, fatigue, fever, mild cough, muscle aches, and nasal congestion. Some cases have also reported gastrointestinal symptoms. Importantly, there is currently no evidence to suggest that NB.1.8.1 causes more severe illness than earlier variants.

Vaccine Efficacy and Booster Recommendations

Despite its mutations, existing COVID-19 vaccines are expected to provide protection against severe disease caused by NB.1.8.1. However, studies indicate that the neutralizing response of antibodies may be reduced against this subvariant, emphasizing the importance of booster doses to maintain immunity.

Health authorities are urging eligible individuals to receive their COVID-19 booster shots, especially as winter approaches in the Southern Hemisphere. In Australia, booster uptake has been low, with only about 6% of adults receiving a booster in the past six months. This decline in vaccination rates raises concerns about the potential for increased hospitalizations and strain on healthcare systems.

Public Health Implications

The emergence of NB.1.8.1 underscores the ongoing evolution of the SARS-CoV-2 virus and the need for continued vigilance. Public health experts recommend the following measures to mitigate the spread of this subvariant:

• Vaccination: Stay up to date with COVID-19 vaccinations, including booster doses as recommended by health authorities.
• Hygiene Practices: Maintain regular handwashing and respiratory hygiene.
• Mask Usage: Wear masks in crowded or poorly ventilated indoor spaces.
• Testing and Isolation: Get tested if experiencing symptoms and isolate if positive to prevent transmission.

As the situation evolves, staying informed through official public health channels is crucial. Continued adherence to recommended preventive measures will be key in managing the impact of NB.1.8.1 and future variants.

For more stories and insights, visit It’s On

Instagram:@itson.ie

TikTok videos and information:@itson.ie